Cardiology

Karol Watson, MD, shares her professional and personal perspective on what a prophylaxis means for especially older VTE patients.

What the Type 2 diabetes treatment could do if approved for cardiovascular events, according to Karol Watson, MD.

A meta-analysis provides no support for theory that incretin-based treatment causes increased mortality in patients with T2D.

High-amylose maize starch with chemical add-ons prevented diabtes in susceptible mice in an Australian study.

Despite its recent success, Morgan Stanley experts give the drug 5% odds of reaching markets.

Pioglitazone actions on reducing insulin resistance could mediate changes in renal function.

The AACE/ACE 2017 recommendations on lipid management prescribe LDL-C targets, and go far lower than any group has ventured to date.

The treatment was tested in a trial of 7,513 patients hospitalized and susceptible to the condition.

The subcutaneous treatment can be used for HAE attacks at home.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

The CANVAS results yield promise against cardiovascular events, but a risk of amputations.

Maternal use of lithium in the first trimester raises risk of cardiac defects to the fetus.

Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.

Her history includes diabetes, ESRD, coronary disease, and complete heart block after pacemaker implantation. What's your ECG read?

Results have major worldwide implications for type 2 diabetes treatment.

New-generation insulin found to have comparable cardiovascular safety to insulin glargine and significantly reduce episodes of severe hypoglycemia.

85% of patients experienced improvement in heart failure symptoms

The FDA determined Sentinel is effective in capturing debris caused by TAVR.

High HbA1c levels after the percutaneous cardiovascular intervention may help identify patients at long-term risk for adverse CV events.

With the global epidemic of obesity showing no signs of waning, physicians should be aware of the cardiac side effects of weight-loss drugs.

Researchers have been investigating whether PCSK9 inhibitors can protect other patients at high risk for a cardiovascular event.

At AAPA 2017 in Las Vegas, Jennifer Carlquist PA-C, ER, CAQ said that she believed clinicians are trained in medicine to think heart disease is "an old person's disease," so they don't have it on their radar for the young people (teen years through mid-30s).

Surgeons can collaborate with pharmacists to reduce medication errors.

What should the new priorities be in congenital heart disease research?

Our author says it's best to assume that any patient with RA is a ticking vascular time bomb. Which statements support that?

A review of Initial presentation and management of acute myocardial infarction.

Study results also showed that levosimendan did not positively affect secondary outcome measures compared to placebo.

Results of a new study indicate an unrecognized systolic dysfunction.

A new study published by The New England Journal of Medicine shows promising results for angiotensin II for treatment-resistant vasodilatory shock.